Search Results 1541-1550 of 19163 for Neutrophil

  1. MC230813 A Study of Golcadomide with Rituximab prior to CAR-T with Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL) - Mayo Clinic

    Absolute neutrophil count (ANC) ≥1000/mcL; growth factor support allowed at physician discretion. Platelet count ≥75,000/mcL; Total bilirubin ≤1.5 x ULN ...

  2. A Study to Evaluate VSV-hIFNbeta-NIS to Treat Patients with Relapsed/Refractory Multiple Myleoma, Acute Myeloid Leukemia, or T-cell Lymphoma - Mayo Clinic

    - FOR MULTIPLE MYELOMA ONLY: Absolute neutrophil count (ANC) >= 1000/uL (obtained =< 14 days prior to registration) - FOR MULTIPLE MYELOMA ONLY: Platelet ...

  3. Ulixertinib in People With Histiocytic Neoplasms - Mayo Clinic

    Adequate bone marrow function (hemoglobin ≥9.0 g/dL, platelets ≥100 x 10^9 cells/L, absolute neutrophil count ≥1.5 x 10^9 cells/L). Patients with ...

  4. A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with GRPR+, ER+, HER2- metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibito - Mayo Clinic

    Absolute neutrophil count ≥ 1.5 × 10^9 /L;; Platelets ≥ 100 × 10^9 /L;; Hemoglobin ≥ 9.0 g/dL;; International Normalized Ratio (INR) ≤ 1.5;; Creatinine ...

  5. Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients - Mayo Clinic

    Absolute Neutrophil count (ANC) < 1.5 × 10^9 /L (may be repeated if 1.0–1.5 × 10^9 /L);; Platelet count < 150 × 10^9 /L (may be repeated if 80–150 × 10^9 /L) ...

  6. Cell and Molecular Aging Laboratory - Mayo Clinic Research

    Neutrophils induce paracrine telomere dysfunction and senescence in ROS-dependent manner. The EMBO Journal. 2021. Anderson R, Lagnado A, Maggiorani D ...

  7. Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) - Mayo Clinic

    Absolute neutrophil count ≥1500/mm3 (granulocyte-colony stimulating factor [G-CSF] administration is not allowed within 1 week prior to screening assessment).

  8. A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) - Mayo Clinic

    Absolute neutrophil count (ANC) ≥ 1.5 × 10^9 /L;; Creatinine clearance ≥ 30 mL/min as calculated using the Cockcroft-Gault equation;; Alanine ...

  9. A Study to Assess the Effectiveness and Safety of Durvalumab Alone or Combined with Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment - Mayo Clinic

    Absolute neutrophil count ≥ 1000/µL;; Platelet count ≥ 65000/µL;; Total bilirubin (TBL) ≤ 2.0 × upper limit of normal (ULN);; Aspartate aminotransferase ...

  10. A Study Evaluating the Safety and Effectiveness of JCAR017 to Treat Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - Mayo Clinic

    ... neutrophil count \>=500mm3 and platelets\>= 75,000/mm3, unless cytopenias are judged by investigator to be due to CLL infiltration of the bone marrow * must ...